|Amlodipine||Calcium channel blocker (dihydropyridine)|
|Trade names||Tekamlo, Rasilamlo|
|AHFS/Drugs.com||Professional Drug Facts|
|(what is this?)|
The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own, with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.
- Pfeiffer D, Rennie N, Papst CC, Zhang J (November 2012). "Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥". Current Vascular Pharmacology. 10 (6): 773–80. doi:10.2174/157016112803520945. PMID 22303911.
- Axthelm C, Sieder C, Meister F, Kaiser E (January 2012). "Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg". Current Medical Research and Opinion. 28 (1): 69–78. doi:10.1185/03007995.2011.637914. PMID 22117838. S2CID 25693979.
- "FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)". U.S. Food and Drug Administration. 19 January 2016.
- "Aliskiren mixture with amlodipine". Drug Information Portal. U.S. National Library of Medicine.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|